A new MRI-based index shows that blood flow closely follows cell density across the layered human cortex and captures aspects ...
Novartis' oral BTK inhibitor remibrutinib (Rhapsido) met its primary endpoint in Phase III REMODEL-1 and REMODEL-2 relapsing ...
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell ...
Christina Applegate's MS misdiagnosis highlights how brain lesions and common symptoms can mislead doctors, with nearly one in five referrals wrong.
A comprehensive review maps how MRI protocols and antibody testing are reshaping the diagnosis of childhood demyelinating ...
For months, multiple sclerosis seemed to explain what was happening to my body. Finding the right diagnosis meant confronting ...
Relapse outcomes were largely null in major RCTs, including SOLAR and VIDAMS, despite numerically lower ARR in some analyses ...
Asianet Newsable on MSN
BMY stock falls 2% after patient death in early multiple sclerosis CAR T trial
The death of the patient with highly active relapsing MS occurred after the study’s data cutoff.
In August 2021, Christina Applegate announced she’d been diagnosed with multiple sclerosis (MS), a chronic, neurodegenerative ...
3d
Novartis Says Remibrutinib Delivers Disease Control in Phase 3 Relapsing Multiple Sclerosis Trials
Novartis (NVS) said Friday that results from two phase 3 trials in relapsing multiple sclerosis showed that remibrutinib reduced the relapse rate and delivered a clinically meanin ...
Novartis presented positive results from the pivotal Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis ...
Multiple sclerosis patients misdiagnosed at rates up to 20%, highlighting diagnostic challenges and the need for improved testing and education.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results